Business

Altamira Therapeutics announced that a private investor has acquired a 51% stake in Altamira Medica, a subsidiary of Altamira that owns Bentrio bentonite nasal spray, which is sold over the counter for the treatment of allergic rhinitis. According to Altamira, the deal includes more than CHF 2 million (~$2.3 million) in cash, and the company will get 25% of future … [Read more...] about Altamira sells majority stake in Bentrio bentonite nasal spray

Inhalon Biopharma has announced that the company received a $5.7 million contract from the United States Army Medical Research and Development Command (USAMRDC) for development of a nebulized therapy against all variants of SARS-CoV-2. The company's web site says that it received the contract for a study of "IN-007, an Inhaled ACE2-Targeting Therapeutic for … [Read more...] about Inhalon Biopharma gets additional funding from the US Army for development of inhaled antibody against SARS-CoV-2

Altamira Therapeutics (formerly Auris Medical) said that the European Patent Office (EPO) has issued a notice that it will grant a patent (No. 3698791) covering the company's AM-125 intranasal formulation of betahistine until February 2038. Altamira says that it has been granted composition of matter and methods of use patents for intranasal betahistine in 50 … [Read more...] about Altamira gets European patent for intranasal betahistine

Transpire Bio, which launched in 2022 to develop inhaled therapeutics for both local and systemic delivery, has officially opened its new headquarters and research facility in Weston, FL, USA. Shortly after launching, the company announced deals with Recipharm for development of 4 inhaled formulations (TRB-1, TRB-2, TRB-3, and TRB-4) and with INTO for 3 additional … [Read more...] about Transpire Bio opens new headquarters and research facility

According to MannKind Corporation, the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,793,808 ("Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them"), which covers the company's MNKD-101 clofazimine inhalation suspension, until 2039. MannKind is developing MNKD-101 … [Read more...] about MannKind gets US patent covering clofazimine inhalation suspension

Qnovia (formerly Respira Technologies) has announced a partnership with researchers at the University of Virginia (UVA) for the development of two new antimicrobial peptides for delivery via the company's RespiRx vibrating mesh nebulizer technology. The new candidates will be called QN-05, which will be developed for the treatment of pneumonia, and QN-06, for the … [Read more...] about Qnovia partners with University of Virginia for development of inhaled antimicrobial peptides

Startup Akita Biosciences, newly launched by faculty members of Brigham & Women's Hospital to develop intranasal therapies, has announced the availability of its first nasal product. The company says that Profi prophylactic nasal spray is "a drug-free formulation composed predominantly of ingredients that have previously been used intranasally at doses higher than … [Read more...] about Akita Biosciences launches Profi antiviral nasal spray

Oragenics will acquire Odyssey Health's breath-powered intranasal delivery device and dry powder nasal formulations, in a deal that includes 8 million shares of Oragenics Series F preferred stock and a total of $1 million in cash, the companies said. The drugs included in the deal are Odyssey's OPN-002 for the treatment of mild traumatic brain injury and ONP-001 for … [Read more...] about Oragenics to acquire Odyssey Health’s nasal delivery technology